News
Ashfield Engage, Alliance Medical and NHS partner to identify early-stage lung cancer
Ashfield Engage, part of UDG Healthcare, has partnered with Alliance Medical to forge a new collaboration delivering the Targeted Lung Health Check (TLHC) programme on behalf of Doncaster and Bassetlaw CCG. The programme is running across 12 pilot sites...
News
FDA Nod Given To Wuxi STA Shanghai Facility After Inspection
WuXi AppTec’s WuXi STA has said that its facility at Waigaoqiao near Shanghai has cleared its first FDA drug product pre-approval inspection. Notably, the U.S. regulator had finished off the inspection in five days last year October. The review...
News
ChargePoint Technology Acquires Terracon Corporation
ChargePoint Technology, the powder transfer specialist, has today announced the acquisition of Terracon Corporation a leader in the design, development, and manufacture of single-use products and accessories for mixing, transferring, and storing liquids and fluids in the biopharma and...
Drug Research
In-Vitro Biology Capabilities Expanded By Piramal Pharma
Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro biology capabilities of its drug discovery service site at Ahmedabad in India.
The new expansion...
Drug Research
Ascletis expands production of ritonavir oral tablets & oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 infection
Ascletis Pharma Inc. announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The company’s Covid-19 pipeline currently includes (i) ritonavir oral tablet (100 mg), an authorized...
Drug Research
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, and ImmunityBio, a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization...
Clinical Trials
Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE, a specialty vaccine company, announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















